Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Xu XL, Liu XD, Liang M, Luo BM. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology 2018;287(2):461–472. https://doi.org/10.1148/radiol.2017162756

Article  PubMed  Google Scholar 

Qin J, Huang Y, Zhou H, Yi S. Efficacy of sorafenib combined with immunotherapy following transarterial chemoembolization for advanced hepatocellular carcinoma: a propensity score analysis. Front Oncol 2022;12:807102. https://doi.org/10.3389/fonc.2022.807102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jihye C, Jinsil S. Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma. Liver Cancer 2012;1(3–4):216–225. https://doi.org/10.1159/000343836

Article  PubMed  PubMed Central  Google Scholar 

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76(3):681–693. https://doi.org/10.1016/j.jhep.2021.11.018

Article  PubMed  Google Scholar 

Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015;21(36):10327–10335. https://doi.org/10.3748/wjg.v21.i36.10327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258(2):627–634. https://doi.org/10.1148/radiol.10101058

Article  PubMed  Google Scholar 

Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci 2020. https://doi.org/10.3390/ijms21218165

Article  PubMed  PubMed Central  Google Scholar 

Llovet JM, Vogel A, Madoff DC, et al. Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Cardiovasc Intervent Radiol 2022;45(4):405–412. https://doi.org/10.1007/s00270-021-03031-9

Article  PubMed  PubMed Central  Google Scholar 

Li D, Pang Y, Xu L, Xu X. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: a meta-analysis. J BUON 2021;26(4):1355–1364

CAS  PubMed  Google Scholar 

Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69(8):1492–1501. https://doi.org/10.1136/gutjnl-2019-318934

Article  PubMed  Google Scholar 

Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013;269(2):603–611. https://doi.org/10.1148/radiol.13130150

Article  PubMed  Google Scholar 

Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol 2023;41(1):117–127. https://doi.org/10.1200/JCO.22.00392

Article  CAS  PubMed  Google Scholar 

Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 2020;72(2):307–319. https://doi.org/10.1016/j.jhep.2019.09.025

Article  CAS  PubMed  Google Scholar 

Korean Liver Cancer Association (KLCA), National Cancer Center (NCC), Goyang, Korea. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20(7):1042–1113. https://doi.org/10.3348/kjr.2019.0140

Article  Google Scholar 

Zhang Z, Li C, Liao W, Huang Y, Wang Z. A combination of sorafenib, an immune checkpoint inihbitor, TACE and stereotactic body radiation therapy versus sorafenib and TACE in advanced hepatocellular carcinoma accompanied by portal vein tumor thrombus. Cancers (Basel) 2022. https://doi.org/10.3390/cancers14153619

Article  PubMed  PubMed Central  Google Scholar 

Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 2020;9(4):452–463. https://doi.org/10.21037/hbsn-20-480

Article  PubMed  PubMed Central  Google Scholar 

Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther 2023;8(1):58. https://doi.org/10.1038/s41392-022-01235-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8(5):336–341. https://doi.org/10.1016/j.ijsu.2010.02.007

Article  PubMed  Google Scholar 

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629

Article  CAS  PubMed  PubMed Central  Google Scholar 

Afshari A, Wetterslev J, Smith AF. Can systematic reviews with sparse data be trusted. Anaesthesia 2017;72(1):12–16. https://doi.org/10.1111/anae.13730

Article  CAS  PubMed  Google Scholar 

Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 2017;17(1):39. https://doi.org/10.1186/s12874-017-0315-7

Article  PubMed  PubMed Central  Google Scholar 

Kang H. Trial sequential analysis: novel approach for meta-analysis. Anesth Pain Med (Seoul) 2021;16(2):138–150. https://doi.org/10.17085/apm.21038

Article  PubMed  Google Scholar 

Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol 2022;13:848387. https://doi.org/10.3389/fimmu.2022.848387

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo P, Pi X, Gao F, et al. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: a propensity score matching study. Front Oncol 2022;12:945915. https://doi.org/10.3389/fonc.2022.945915

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qu WF, Ding ZB, Qu XD, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open 2022. https://doi.org/10.1093/bjsopen/zrac114

Article  PubMed  PubMed Central  Google Scholar 

Yang XG, Sun YY, Wang HQ, Li DS, Xu GH, Huang XQ. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: a propensity score matching analysis. Front Oncol 2022;12:914385. https://doi.org/10.3389/fonc.2022.914385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng L, Fang S, Wu F, et al. Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study. Front Mol Biosci 2020;7:609322. https://doi.org/10.3389/fmolb.2020.609322

Article  CAS  PubMed  Google Scholar 

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019

Article  Google Scholar 

Kontopantelis E, Reeves D. Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: a simulation study. Stat Methods Med Res 2012;21(4):409–426. https://doi.org/10.1177/0962280210392008

Article  PubMed  Google Scholar 

Feng JK, Liu ZH, Fu ZG, et al. Efficacy and safety of transarterial chemoembolization plus antiangiogenic-targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world. Front Oncol 2022;12:954203. https://doi.org/10.3389/fonc.2022.954203

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Xu X, Meng F, et al. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a review. Front Oncol 2022;12:980214. https://doi.org/10.3389/fonc.2022.980214

Article  CAS  PubMed  PubMed Central  Google Scholar